Levels of bone turnover markers (N-terminal propeptide of type I procollagen and carboxy-terminal telopeptide of type I collagen) in Ukrainian population of different age and gender

Main Article Content

V.V. Povoroznyuk
I.V. Pankiv
N.V. Zaverukha
T.Yu. Solonenko
A.S. Musiienko

Abstract

Background. The purpose was to determine the level of N-terminal of type I procollagen (PINP) and carboxy-terminal telopeptide of type I collagen (β-CTX) and their relationship in the serum of a healthy Ukrainian population of varying age and gender. Materials and methods. The study included 3,850 people aged 20–89 years (3,351 women (mean age 59.05 ± 13.89 years) and 499 men (49.17 ± 15.8 years). All participants were divided by age based on the gerontological age classification: young age 20–44 yrs, middle age 45–59 yrs, elderly 60–74 yrs, and old 75–89 yrs, and between 7 groups by decades: from 20 to 89. β-CTX and serum PINP concentrations were determined by electrochemiluminescence immunoassay ECLIA on a Cobas E411 analyzer. Results. We have detected a significant effect of age on serum β-CTX and PINP variability in men (F = 6.64, p < 0.001 and F = 4.93, p < 0.001) and women (F = 16.17, p < 0.001 and F = 10.46, p < 0.001, respectively). By Scheffe test detected a significantly higher level of β-CTX in the group of in women of 80–89 years compared with the groups of 20–29 years (p = 0.01), 30–39 years (p < 0.001), 40–49 years (p < 0.001), 50–59 years (0.52 ± 0.27, p = 0.002), 60–69 years (p = 0.001), and 70–79 years (p = 0.04). PINP rates in the group of 80–89 years were also significantly higher compared with the groups of 30–39 years (p < 0.001), 40–49 years (p < 0.001), 50–59 years (p = 0.009), 60–69 years (p = 0.002), and 70–79 years (p = 0.02). In men, a significant decrease in the concentration of β-CTX was revealed in the groups of: 30–39 years (p = 0.02), 40–49 years (p < 0.001), 50–59 years (p = 0.01), and 60–69 years (p = 0.001) compared with the group of 20–29 years. The level of PINP was significantly lower in the groups of 40–49 years (p < 0.001) and 50–59 years (p = 0.03) compared with the group of 20–29 years. According to the results of the study, the correlation coefficient between the concentration of PINP and β-CTX varies depending on age and sex. The highest correlation coefficients among both sexes were observed in the age groups of 40–49 years (women: r = 0.74; men: r = 0.64) and 50–59 (women: r = 0.74; men: r = 0.66); the lowest correlation coefficients were observed in women in the age group of 20–29 years (r = 0.63) and 70–79 (r = 0.65); in men (r = 0.53) aged 20–29 and 70–79 years. Conclusions. It was detected a significant effect of age on serum variability of β-CTX and PINP in men and women. The highest dependence of β-CTX concentration on PINP by the coefficient of determination was observed in the groups of 40–49 and 50–59 years among both genders. The results can be used as a reference in almost healthy men and women, which in the future will be used for the research of bone metabolism in secondary osteoporosis and its complications.

Article Details

How to Cite
Povoroznyuk, V., I. Pankiv, N. Zaverukha, T. Solonenko, and A. Musiienko. “Levels of Bone Turnover Markers (N-Terminal Propeptide of Type I Procollagen and Carboxy-Terminal Telopeptide of Type I Collagen) in Ukrainian Population of Different Age and Gender”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 7, Mar. 2021, pp. 515-2, doi:10.22141/2224-0721.16.7.2020.219005.
Section
Original Researches

References

Williams C, Sapra A. Osteoporosis Markers. 2020 Jun 10. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559306/. Accessed: June 10, 2020.

Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017 May 18;5:18. doi:10.1186/s40364-017-0097-4.

Povoroznyuk VV, Zaverukha NV, Solonenko TYu. Serum level of N-terminal propeptide of type I procollagen in people of various ages and gender. Bolʹ, sustavy, pozvonočnik. 2020;10(1):1-8. doi:10.22141/2224-1507.10.1.2020.199719. (in Ukrainian).

Cabral HW, Andolphi BF, Ferreira BV, et al. The use of biomarkers in clinical osteoporosis. Rev Assoc Med Bras (1992). 2016 Jul;62(4):368-76. doi:10.1590/1806-9282.62.04.368.

Bhattoa HP. Laboratory aspects and clinical utility of bone turnover markers. EJIFCC. 2018 Jul 11;29(2):117-128.

Burch J, Rice S, Yang H, et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technol Assess. 2014 Feb;18(11):1-180. doi:10.3310/hta18110.

International Osteoporosis Foundation (IOF). About osteoporosis. Available from: https://www.iofbonehealth.org/what-is-osteoporosis.

Szulc P, Naylor K, Hoyle NR, Eastell R, Leary ET; National Bone Health Alliance Bone Turnover Marker Project. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017 Sep;28(9):2541-2556. doi:10.1007/s00198-017-4082-4.

Tian A, Ma J, Feng K, et al. Reference markers of bone turnover for prediction of fracture: a meta-analysis. J Orthop Surg Res. 2019 Feb 28;14(1):68. doi:10.1186/s13018-019-1100-6.

Eastell R, Pigott T, Gossiel F, Naylor KE, Walsh JS, Peel NFA. Diagnosis of endocrine disease: Bone turnover markers: are they clinically useful? Eur J Endocrinol. 2018 Jan;178(1):R19-R31. doi:10.1530/EJE-17-0585.

Coates P. Bone turnover markers. Aust Fam Physician. 2013 May;42(5):285-7.

Kraus VB, Blanco FJ, Englund M, et al. OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage. 2015 May;23(5):686-6 97. doi:10.1016/j.joca.2015.03.002.

Institute of Medicine (US) Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Micheel CM, Ball JR, editors. Washington (DC): National Academies Press (US); 2010. doi:10.17226/12869.

Abril DW. Mechanical behavior of individual type I collagen fibrils. Rev Bras Ergon. 2016;9:10.

Burch J, Rice S, Yang H, et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technol Assess. 2014 Feb;18(11):1-180. doi:10.3310/hta18110.

Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 2009;78:929-58. doi:10.1146/annurev.biochem.77.032207.120833.

Garnero P. Bone markers in osteoporosis. Curr Osteoporos Rep. 2009 Sep;7(3):84-90. doi:10.1007/s11914-009-0014-3.

Shetty S, Kapoor N, Bondu JD, Thomas N, Paul TV. Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J Endocrinol Metab. 2016 Nov-Dec;20(6):846-852. doi:10.4103/2230-8210.192914.

Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011 Feb;22(2):391-420. doi:10.1007/s00198-010-1501-1.

Chubb SA. Measurement of C-terminal telopeptide of type I collagen (CTX) in serum. Clin Biochem. 2012 Aug;45(12):928-935. doi:10.1016/j.clinbiochem.2012.03.035.

Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 update. Endocr Pract. 2020 May;26(Suppl 1):1-46. doi:10.4158/GL-2020-0524SUPPL.

Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO); Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2020 Jan;31(1):209. doi:10.1007/s00198-019-05184-3.

Chapurlat RD. Bone turnover markers in clinical practice. In: World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases: Abstract Book. August 20-22, 2020; Virtual Congress. Amsterdam, the Netherlands: WCO-IOF-ESCEO; 2020. 33 p.

Kanis JA, Johansson H, Harvey NC, McCloskey EV. A brief history of FRAX. Arch Osteoporos. 2018 Oct 31;13(1):118. doi:10.1007/s11657-018-0510-0.

National Institute for Health and Care Excellence (NICE); Health and Social Care Directorate. Quality standards and indicators: briefing paper 2017. London, UK: NICE; 2018. 1-45 pp.

Eastell R, Black DM, Lui LY, et al. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained. J Bone Miner Res. 2020 Sep 11. doi:10.1002/jbmr.4178.

Bauer DC, Black DM, Bouxsein ML, et al. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. J Bone Miner Res. 2018 Apr;33(4):634-642. doi:10.1002/jbmr.3355.

Crandall CJ, Vasan S, LaCroix A, et al. Bone Turnover Markers Are Not Associated With Hip Fracture Risk: A Case-Control Study in the Women's Health Initiative. J Bone Miner Res. 2018 Jul;33(7):1199-1208. doi:10.1002/jbmr.3471.

Diez-Perez A, Naylor KE, Abrahamsen B, et al. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017 Mar;28(3):767-774. doi:10.1007/s00198-017-3906-6.

Gutierrez-Buey G, Restituto P, Botella S, et al. Trabecular bone score and bone remodelling markers identify perimenopausal women at high risk of bone loss. Clin Endocrinol (Oxf). 2019 Sep;91(3):391-399. doi:10.1111/cen.14042.

Verroken C, Zmierczak HG, Goemaere S, Kaufman JM, Lapauw B. Bone Turnover in Young Adult Men: Cross-Sectional Determinants and Associations With Prospectively Assessed Bone Loss. J Bone Miner Res. 2018 Feb;33(2):261-268. doi:10.1002/jbmr.3303.

Lorentzon M, Branco J, Brandi ML, et al. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Adv Ther. 2019 Oct;36(10):2811-2824. doi:10.1007/s12325-019-01063-9.

Cooper C, Ferrari S; International Osteoporosis Foundation (IOF). IOF Compendium of Osteoporosis. 2nd ed. Nyon, Switzerland: IOF; 2019. 1-76 pp.

Chapurlat RD. Bone turnover markers in clinical practice. In: World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases: Abstract Book. August 20-22, 2020; Virtual Congress. Amsterdam, the Netherlands: WCO-IOF-ESCEO; 2020. 33 p.

Most read articles by the same author(s)

1 2 3 4 > >>